Novavax, Inc. (NVAX)

$3.95

-0.2

(-4.82%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Novavax, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 22.06M → 291.34M (in $), with an average increase of 92.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 58.00M → -178.38M (in $), with an average decrease of 180.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.9% return, outperforming this stock by 97.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.5% return, outperforming this stock by 338.6%

Performance

  • $3.91
    $4.06
    $3.95
    downward going graph

    1.01%

    Downside

    Day's Volatility :3.69%

    Upside

    2.71%

    downward going graph
  • $3.53
    $11.36
    $3.95
    downward going graph

    10.63%

    Downside

    52 Weeks Volatility :68.93%

    Upside

    65.23%

    downward going graph

Returns

PeriodNovavax, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
1.22%
1.1%
0.0%
6 Months
-33.81%
12.5%
0.0%
1 Year
-45.61%
6.9%
2.2%
3 Years
-98.13%
14.3%
-23.0%

Highlights

Market Capitalization
586.4M
Book Value
- $5.14
Earnings Per Share (EPS)
-5.41
PEG Ratio
0.0
Wall Street Target Price
15.4
Profit Margin
-55.41%
Operating Margin TTM
-63.01%
Return On Assets TTM
-17.02%
Return On Equity TTM
-898.2%
Revenue TTM
983.7M
Revenue Per Share TTM
9.76
Quarterly Revenue Growth YOY
-18.5%
Gross Profit TTM
-156.0M
EBITDA
-511.0M
Diluted Eps TTM
-5.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.73
EPS Estimate Next Year
-0.05
EPS Estimate Current Quarter
-0.45
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    66%Buy
    16%Hold
    16%Sell
Based on 12 Wall street analysts offering stock ratings for Novavax, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
2
Hold
2
2
5
Sell
2
2
5

Analyst Forecast

What analysts predicted

Upside of 289.87%

Current $3.95
Target $15.40

Company Financials

FY18Y/Y Change
Revenue
34.3M
↑ 9.98%
Net Income
-184.7M
↑ 0.53%
Net Profit Margin
-538.81%
↑ 50.65%
FY19Y/Y Change
Revenue
18.7M
↓ 45.57%
Net Income
-130.1M
↓ 29.58%
Net Profit Margin
-697.15%
↓ 158.34%
FY20Y/Y Change
Revenue
475.6M
↑ 2448.48%
Net Income
-427.5M
↑ 228.59%
Net Profit Margin
-89.89%
↑ 607.26%
FY21Y/Y Change
Revenue
1.1B
↑ 141.02%
Net Income
-1.7B
↑ 307.89%
Net Profit Margin
-152.12%
↓ 62.23%
FY22Y/Y Change
Revenue
1.6B
↑ 39.49%
Net Income
-657.9M
↓ 62.27%
Net Profit Margin
-41.15%
↑ 110.97%
FY23Y/Y Change
Revenue
983.7M
↓ 38.48%
Net Income
-545.1M
↓ 17.16%
Net Profit Margin
-55.41%
↓ 14.26%
Q3 FY22Q/Q Change
Revenue
734.6M
↑ 295.09%
Net Income
-168.6M
↓ 66.97%
Net Profit Margin
-22.95%
↑ 251.62%
Q4 FY22Q/Q Change
Revenue
287.8M
↓ 60.82%
Net Income
-182.2M
↑ 8.09%
Net Profit Margin
-63.32%
↓ 40.37%
Q1 FY23Q/Q Change
Revenue
81.0M
↓ 71.88%
Net Income
-293.9M
↑ 61.27%
Net Profit Margin
-363.07%
↓ 299.75%
Q2 FY23Q/Q Change
Revenue
424.4M
↑ 424.3%
Net Income
58.0M
↓ 119.74%
Net Profit Margin
13.67%
↑ 376.74%
Q3 FY23Q/Q Change
Revenue
22.1M
↓ 94.8%
Net Income
-130.8M
↓ 325.44%
Net Profit Margin
-592.71%
↓ 606.38%
Q4 FY23Q/Q Change
Revenue
291.3M
↑ 1220.44%
Net Income
-178.4M
↑ 36.41%
Net Profit Margin
-61.23%
↑ 531.48%
FY18Y/Y Change
Total Assets
208.0M
↓ 31.25%
Total Liabilities
375.9M
↓ 7.0%
FY19Y/Y Change
Total Assets
173.0M
↓ 16.84%
Total Liabilities
359.0M
↓ 4.51%
FY20Y/Y Change
Total Assets
1.6B
↑ 814.96%
Total Liabilities
955.3M
↑ 166.11%
FY21Y/Y Change
Total Assets
2.6B
↑ 62.83%
Total Liabilities
2.9B
↑ 206.55%
FY22Y/Y Change
Total Assets
2.3B
↓ 12.34%
Total Liabilities
2.9B
↓ 1.22%
FY23Y/Y Change
Total Assets
1.9B
↓ 17.86%
Total Liabilities
2.6B
↓ 11.08%
Q3 FY22Q/Q Change
Total Assets
2.3B
↓ 13.56%
Total Liabilities
2.8B
↓ 6.79%
Q4 FY22Q/Q Change
Total Assets
2.3B
↓ 0.39%
Total Liabilities
2.9B
↑ 2.09%
Q1 FY23Q/Q Change
Total Assets
1.5B
↓ 31.7%
Total Liabilities
2.4B
↓ 15.71%
Q2 FY23Q/Q Change
Total Assets
1.7B
↑ 9.23%
Total Liabilities
2.4B
↑ 0.05%
Q3 FY23Q/Q Change
Total Assets
1.7B
↓ 1.66%
Total Liabilities
2.3B
↓ 4.27%
Q4 FY23Q/Q Change
Total Assets
1.9B
↑ 11.96%
Total Liabilities
2.6B
↑ 10.14%
FY18Y/Y Change
Operating Cash Flow
-184.8M
↑ 33.26%
Investing Cash Flow
28.6M
↓ 20.5%
Financing Cash Flow
102.8M
↑ 59.29%
FY19Y/Y Change
Operating Cash Flow
-136.6M
↓ 26.08%
Investing Cash Flow
38.5M
↑ 34.61%
Financing Cash Flow
98.4M
↓ 4.3%
FY20Y/Y Change
Operating Cash Flow
-42.5M
↓ 68.86%
Investing Cash Flow
-377.8M
↓ 1081.45%
Financing Cash Flow
984.8M
↑ 900.94%
FY21Y/Y Change
Operating Cash Flow
322.9M
↓ 859.14%
Investing Cash Flow
100.2M
↓ 126.51%
Financing Cash Flow
461.7M
↓ 53.11%
FY22Y/Y Change
Operating Cash Flow
-415.9M
↓ 228.79%
Investing Cash Flow
-93.0M
↓ 192.84%
Financing Cash Flow
325.0M
↓ 29.61%
Q3 FY22Q/Q Change
Operating Cash Flow
-38.7M
↓ 77.35%
Investing Cash Flow
-29.5M
↑ 20.11%
Financing Cash Flow
-31.0M
↓ 764.86%
Q4 FY22Q/Q Change
Operating Cash Flow
-117.8M
↑ 204.37%
Investing Cash Flow
-22.1M
↓ 25.25%
Financing Cash Flow
191.4M
↓ 718.03%
Q1 FY23Q/Q Change
Operating Cash Flow
-325.6M
↑ 176.36%
Investing Cash Flow
-7.8M
↓ 64.74%
Financing Cash Flow
-354.4M
↓ 285.11%
Q2 FY23Q/Q Change
Operating Cash Flow
-171.9M
↓ 47.19%
Investing Cash Flow
-7.8M
↑ 0.0%
Financing Cash Flow
61.3M
↓ 117.31%
Q3 FY23Q/Q Change
Operating Cash Flow
-39.7M
↓ 76.94%
Investing Cash Flow
-18.4M
↑ 136.42%
Financing Cash Flow
197.1M
↑ 221.38%

Technicals Summary

Sell

Neutral

Buy

Novavax, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Novavax, Inc.
Novavax, Inc.
-13.72%
-33.81%
-45.61%
-98.13%
-58.88%
Moderna, Inc.
Moderna, Inc.
1.34%
41.81%
-16.73%
-38.71%
314.51%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.23%
10.39%
23.96%
84.71%
131.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Novavax, Inc.
Novavax, Inc.
NA
NA
0.0
-0.73
-8.98
-0.17
NA
-5.14
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Novavax, Inc.
Novavax, Inc.
Buy
$586.4M
-58.88%
NA
-55.41%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
314.51%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
131.85%
29.17
36.68%

Institutional Holdings

  • State Street Corporation

    11.99%

  • Vanguard Group Inc

    10.40%

  • BlackRock Inc

    6.03%

  • Shah Capital Management

    5.56%

  • Morgan Stanley - Brokerage Accounts

    5.17%

  • Geode Capital Management, LLC

    1.64%

Corporate Announcements

  • Novavax, Inc. Earnings

    Novavax, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Novavax, Inc. is a biotechnology company focused on delivering novel products that effectively use innovative technology to solve known and emerging disease threats. The biotechnology giant is dedicated to creating cost-effective and democratized vaccine solutions for infectious diseases, such as seasonal flu, Ebola, COVID-19, and more. Founded in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland. It specializes in developing recombinant vaccines, and its lineup includes NVX-CoV2373, NanFlu, and ResVax, helpful in treating or preventing coronavirus, seasonal quadrivalent influenza, and a respiratory syncytial virus, respectively. Novavax, Inc. is also testing Matrix-M and its EBOV vaccine candidate in the Phase I clinical trial. It is also developing additional pre-clinical stage vaccine programs for occurrences such as MERS. It presently has over 750 employees, and its Nuvaxovid, a COVID-19 solution, is the fifth approved vaccine in the European Union. Further, Novavax has also filed the complete CMC data package with the FDA. It combines Novavax’s manufacturing prowess with Serum Institute of India Pvt. Ltd. (SII)’s experience for improved vaccine manufacturing. In addition, it also purchased Praha Vaccines and its vaccine factory in the Czech Republic, having a capacity of 1 billion doses per year. Currently Novavax, Inc. has a market cap of $0.59 Billion. It has a P.E ratio of -1.08. The shares of Novavax, Inc. are trading at $4.15. .

Organization
Novavax, Inc.
Employees
1543
CEO
Mr. John Joseph Trizzino B.S., M.B.A.
Industry
Health Technology

Discover More

FAQs